Safety study: is there a pathologic IGF-1, PDGF and TGF-β cytokine expression caused by adjunct BMP-7 in tibial and femoral non-union therapy?

**Background:** In this prospective safety study, we investigated if the characteristic cytokine expression during bone regeneration is manipulated by the local application of bone morphogenetic protein-7 (BMP-7) in non-union surgery. Therefore, the levels of insulin like growth factor 1 (IGF-1), platelet-derived growth factor AB (PDGF-AB) and transforming growth factor beta (TGF-β) were compared between patients with the gold standard use of autologous bone graft (ABG) and those with additional application of BMP-7 as part of the diamond concept.

**Patients and methods:** Between 2009 and 2014, of the 153 patients with tibial and femoral non-unions, a matched pair analysis was performed to compare the serological cytokine expressions. Blood samples were collected preoperatively, 1, 2 and 6 weeks as well as 3 and 6 months after non-union surgery. Matching criteria were smoking status, fracture location, gender, age and body mass index (BMI). Patients in G1 (n=10) were treated with ABG and local BMP-7 while their matching partners in G2 (n=10) received ABG only. The routine clinical and radiologic follow-up was 1 year.

**Results:** Although the IGF-1 quantification in G2 showed higher pre- and postoperative values compared to G1 (p<0.05), the courses of both groups were similar. Likewise, PDGF-AB and TGF-β expressions appeared similar in G1 and G2 with peaks in both groups at 2 weeks follow-up. Osseous consolidation was assessed in all operated non-unions. The adjunct application of BMP-7 did not cause any pathologic cytokine expression.

**Conclusion:** Similar expressions of the serum cytokines IGF-1, PDGF-AB and TGF-β were demonstrated in non-union patients treated with ABG and additional application of BMP-7 according to the diamond concept. Our findings indicate that the local application of BMP-7, which imitates the physiologic secretion of growth factors during bone regeneration, is safe and without the risk of abnormal systemic cytokine expression. Studies with higher patient numbers will have to validate these assumptions.

**Keywords:** bone morphogenetic protein, cytokine, non-union, safety

**Introduction**

There are 10% of long bone fractures that do not heal and evolve non-unions. In patients at special risk, this rate can reach up to 30%. Multiple therapeutic options for the treatment of non-unions include debridement, implant replacement and transplantation of autologous bone grafts (ABGs) that contain mesenchymal stem cells (MSCs) and combine osteoinductive, osteoconductive and osteogenic effects. The diamond concept, as an alternative non-union treatment concept, includes mechanical stability and additional use of growth factors like BMP-7 (Osigraft®; Olympus Biotech Europe, Lyon, France) and matrix scaffolds because a successful treatment depends on an
optimal mechanical and biological environment. This holistic concept has been proven to be effective in the treatment of atrophic non-unions.\(^8\)\(^{–}\)\(^{10}\)

Bone regeneration and fracture healing are influenced by growth factors and cytokines as has been reported before.\(^{11}\)\(^{–}\)\(^{15}\) Specifically, the insulin-like growth factor 1 (IGF-1), platelet-derived growth factor AB (PDGF-AB) and the transforming growth factor beta (TGF-\(\beta\)) are cytokines that ensure physiologic osseous regeneration.\(^{16}\)\(^{–}\)\(^{20}\) IGF-1, which serves as a regulator during bone turnover, has autocrine functions inside the fracture callus and facilitates the proliferation and differentiation of osteoprogenitor cells.\(^{17}\)\(^{–}\)\(^{25}\) Low IGF-1 expressions have been demonstrated in non-union patients.\(^{22}\) PDGF-AB, which controls the inflammatory response,\(^{26}\)\(^{27}\) is released early during the fracture-healing cascade and promotes the revascularization at the fracture site.\(^{15}\)\(^{17}\)\(^{28}\)\(^{29}\) An increased concentration of PDGF-AB in patients’ sera with regular bone healing as well as its positive effect on fracture healing has been proven,\(^{26}\)\(^{28}\) whereas lower PDGF-AB levels have been observed in patients with non-unions.\(^{20}\) TGF-\(\beta\), as a substantial promoter for fracture healing and bone remodeling,\(^{30}\) plays a significant role in the early phases of bone metabolism.\(^{31}\) While stimulating the mobilization of bone marrow MSCs and osteoprogenitor cells, it is also a chemotactic promoter of osteogenic differentiation.\(^{14}\)\(^{17}\)\(^{32}\)\(^{33}\) Consequently, the promotion through TGF-\(\beta\) leads to the formation of osteoblasts and eventually to new bone formation.\(^{11}\)\(^{30}\)\(^{34}\)

Clinical studies have demonstrated the effect of additional BMP-7 to foster non-union consolidation.\(^{35}\) Recently, similar PDGF and TGF-\(\beta\) expressions have been demonstrated in fracture patients with proper healing and in non-union patients treated with BMP-7.\(^{36}\) As non-union patients treated with BMP-7 show increased expression patterns for angiogenic and inflammable cytokines like IL-6, we wanted to analyze if this was also true for cytokines like IGF-1, PDGF-AB and TGF-\(\beta\) whose disturbance is rated as carcinogenetic factor.\(^{38}\)\(^{–}\)\(^{41}\) Therefore, in this study, we applied a standardized long-term cytokine protocol which comprised blood samplings before and until 6 months after non-union revision surgery at six different points of time. Peripheral blood concentrations of IGF-1, PDGF-AB and TGF-\(\beta\) were used as objective monitoring criteria on a molecular level to assess if the adjunct application of BMP-7 within the diamond concept causes pathologic stimulation of cytokines in comparison to the mere transplantation of ABG.\(^3\)

Our hypothesis was that the administration of BMP-7 in non-union surgery is safe and does not disturb the physiological expression of IGF-1, PDGF-AB and TGF-\(\beta\) during bone regeneration.

Patients and methods

Patients

This prospective, controlled study was conducted in accordance with the declaration of Helsinki, approved by both the ethics committee of the Ruprecht-Karls-University of Heidelberg (157/2002 and S-636/2011) and the ethics committee of the medical association Rheinland-Pfalz (837.422.12). Between 2009 and 2014, we registered 153 patients with tibial or femoral fracture non-unions who received revision surgery at one of the two participating primary trauma centers. All patients provided written informed consent to participate in this research. Inclusion criteria were the minimum age of 18 years, the presence of a fracture non-union, clinical and radiologic follow-up over at least 12 months (Figure 1) and the formal agreement with the study. Patients with a history of malignoma or inflammatory diseases as well as long-term use of immunosuppressive drugs were excluded.

Out of this non-union register, 20 patients were matched into pairs (Figure 2): 10 patients received ABG plus BMP-7 (G1) and 10 patients received ABG transplantation alone (G2). Specific matching criteria were “smoking”, as it is known for its impact on bone healing,\(^1\) fracture location (tibia or femur) and gender. Subordinated criteria in our matched pair analysis were age and body mass index.

Figure 1 Perioperative X-rays of a femoral non-union.
Notes: Before non-union treatment according to the diamond concept (A) and 6 months postoperatively when consolidation was achieved (B). The intramedullary nail was removed, the non-union resected and the gap was filled with ABG (autologous bone graft), 3.3 mg BMP-7 and a tricalcium phosphate bone graft (Vitoss; Stryker, Duisburg, Germany). Re-osteosynthesis was performed with an angled blade plate.
Physiologic growth factor expression in non-union therapy with BMP-7 (BMI). The patients’ smoking status was defined by their cotinine status and a questionnaire. The cotinine status was measured according to the standardized procedure of the manufacturer (Cotinine Direct ELISA Kit; Nal Von Minden, Maarn, the Netherlands).

G1 group included 10 patients (seven females, three males) with a mean age of 48.8 years and an average BMI of 29.1 kg/m$^2$ (range, 20.3–41.8 kg/m$^2$). Five patients were declared to be smokers and tested positive for cotinine. G2 group contained 10 patients (seven females, three males) with a mean age of 49.4 years and a mean BMI of 25.6 kg/m$^2$ (range, 18 to 39.5 kg/m$^2$). Four patients were tested positive for cotinine (Table 1).

Sample acquisition

The cytokine expressions of IGF-1, PDGF-AB and TGF-β were analyzed according to an established cytokine protocol (Figure 3) in blood samples collected preoperatively, 1, 2 and 6 weeks as well as 3 and 6 months after surgery (S-Monovette 7.5 mL serum tubes; Sarstedt AG, Nümbrecht, Germany). The preoperative value was needed to establish an initial group-specific level before any interference by surgery. The samples were centrifuged at 3,000 rpm for 10 minutes at a temperature of 15°C. Afterward, the supernatant obtained from the serum samples was removed and pipetted into Eppendorf tubes before being stored at −80°C.

Surgical procedure

After implant removal, debridement and re-osteosynthesis, we used ABG mixed with 3.3 mg BMP-7 (G1) and ABG only (G2) to fill the non-union gap. The ABG was generated via reamer irrigator aspirator (RIA) technique from the opposite femur or harvested from the iliac crest.

Data analysis

Due to the abnormal distribution of the data, nonparametric tests were used to compare samples. Statistical analysis for independent variables (different groups) was realized with the Mann–Whitney U-test, and dependent variables (within one group) were compared with the Wilcoxon’s signed-rank test. The serum levels of the analyzed cytokines at different points
of time were expressed as absolute mean concentrations ± standard deviation.

Statistical significance was determined for $p$-values <0.05. Statistical analyses were performed with SPSS 24 for Windows (IBM Corporation, Armonk, NY, USA). Graphs were created with Sigmaplot software (Systat Software Inc., San Jose, CA, USA).

**Results**

The specific characteristics of the matched patients in G1 and G2 groups are summarized in Table 1. All operated non-unions showed eventual consolidation at 12 months follow-up. The group-specific cytokine expressions were as follows:

**IGF-1**

The course of IGF-1 expression was similar in both G1 and G2 groups, with higher levels in the G2 group throughout the entire period (Figure 4A). In G1 group, the mean

---

**Figure 3** Timeline of sample acquisition according to a standardized cytokine protocol.

**Figure 4** Analysis of sequential IGF-1 (A), PDGF-AB (B) and TGF-β (C) expression levels of G1 (autologous bone graft with additional BMP-7) and G2 (autologous bone graft alone) groups expressed as absolute mean concentrations ± standard deviation.

**Notes:** Serum concentration was measured in picograms per milliliter (pg/mL). The Wilcoxon’s signed-rank test assessed significant differences between both groups at each particular time point (*indicates significant differences, $p<0.05$).
Physiologic growth factor expression in non-union therapy with BMP-7

Therapeutics and Clinical Risk Management downloaded from https://www.dovepress.com/ by 54.70.40.11 on 22-Sep-2019
For personal use only.

Therapeutics and Clinical Risk Management 2018:14

Therapeutics and Clinical Risk Management downloaded from https://www.dovepress.com/ by 54.70.40.11 on 22-Sep-2019
For personal use only.

Therapeutics and Clinical Risk Management downloaded from https://www.dovepress.com/ by 54.70.40.11 on 22-Sep-2019
For personal use only.

Therapeutics and Clinical Risk Management downloaded from https://www.dovepress.com/ by 54.70.40.11 on 22-Sep-2019
For personal use only.

Therapeutics and Clinical Risk Management downloaded from https://www.dovepress.com/ by 54.70.40.11 on 22-Sep-2019
For personal use only.

Therapeutics and Clinical Risk Management downloaded from https://www.dovepress.com/ by 54.70.40.11 on 22-Sep-2019
For personal use only.

Therapeutics and Clinical Risk Management downloaded from https://www.dovepress.com/ by 54.70.40.11 on 22-Sep-2019
For personal use only.

Therapeutics and Clinical Risk Management downloaded from https://www.dovepress.com/ by 54.70.40.11 on 22-Sep-2019
For personal use only.

Therapeutics and Clinical Risk Management downloaded from https://www.dovepress.com/ by 54.70.40.11 on 22-Sep-2019
For personal use only.

Therapeutics and Clinical Risk Management downloaded from https://www.dovepress.com/ by 54.70.40.11 on 22-Sep-2019
For personal use only.

concentration dropped from 70.2 pg/mL preoperatively to 45.5 pg/mL at 1 week, followed by a significant increase to its maximum at 6 weeks (74.1 pg/mL; \( p=0.037 \)). At 6 months, the level was still significantly higher than at 1 week (\( p=0.038 \)). In G2 group, the mean concentration dropped from 107.6 pg/mL preoperatively to 74.8 pg/mL at 1 week, followed by a significant increase to its maximum at 3 months (119.0 pg/mL). At 6 months, the level was still significantly higher than at 1 week (\( p=0.021 \)).

**PDGF-AB**

The mean concentrations in both the groups were almost equivalent over the entire period (Figure 4B). In G1 group, the mean concentration dropped from 14,973.0 pg/mL preoperatively to 12,968.9 pg/mL at 1 week, followed by an increase to a maximum at 2 weeks (17,051.4 pg/mL). From this point, it slowly declined to the 6-month level (14,357.3 pg/mL). In G2 group, the mean concentration dropped from 14,088.3 pg/mL preoperatively to 12,496.7 pg/mL at 1 week, followed by an increase to a maximum at 2 weeks (16,637.5 pg/mL). From this point, it declined to the 6-month level (14,263.2 pg/mL).

**TGF-β**

As before, G1 and G2 groups demonstrated almost equivalent expressions over the monitoring period with consistently higher levels in G1 group (Figure 4C). In G1 group, the mean concentration dropped from 49,580.4 pg/mL preoperatively to 45,609.8 pg/mL at 1 week, followed by an increase to a maximum at 2 weeks (57,281.1 pg/mL). After further decline until 6 weeks (50,169.56 pg/mL), the course of the TGF-β levels remained almost constant. In G2 group, the mean concentration dropped from 44,591.1 pg/mL preoperatively to 39,644.4 pg/mL at 1 week, followed by an increase to a maximum at 2 weeks (51,633.3 pg/mL). From this point, it declined to the 6-week level (42,908.6 pg/mL) followed by a slight increase at 3 months (46,475.6 pg/mL), and the concentration remained almost steady thereafter.

**Discussion**

The aim of this prospective safety study was to evaluate the biological impact of additional BMP-7 administration in non-union therapy on a molecular level comparing the growth factor expression levels of IGF-1, PDGF-AB and TGF-β to those of patients with ABG alone as gold standard. The selection of IGF-1, PDGF-AB and TGF-β for this study was based on their importance in bone regeneration and coincidental expression in cancer patients.38-41 Our results showed uniform courses of all three serum cytokines in G1 and G2 groups at different stages of the postoperative follow-up period. None of the measured cytokines demonstrated any pathologic reaction to the treatment with BMP-7 according to the diamond concept.

Interestingly, IGF-1 levels were lower in G1 than in G2 group throughout the entire measurements; however, the exact reason for this difference remains unclear. Based on the sequential measurements that included the preoperative IGF-1 expression levels, this difference is unlikely to be caused by the index surgery. The postoperative expression of IGF-1 with an explicit and steady rise after 1 week until 6 weeks in G1 and 12 weeks in G2 groups could equally be demonstrated in our preliminary studies,23,44 and high concentrations were also detected during fracture callus formation.22

The absolute values of PDGF-AB were almost identical in G1 and G2 groups. The steep increase to its 2-week maximum after an initial decrease can especially be traced back to the effect of PDGF-AB on the early phases of fracture healing.26

In preliminary studies, high PDGF-AB concentrations have been shown in patients with regular fracture healing as well as after successful non-union therapy.36,44 Similarly, almost no differences regarding the expression of TGF-β could be noticed between the two study groups with one peak after 2 weeks. Preliminary studies confirmed this typical increase of TGF-β at an early stage of fracture healing which could also be found for PDGF-AB. Certain “co-regulation functions” of these two cytokines could play a role.23

The treatment of a non-union with growth factors like BMP-7 is an important part of the diamond concept.6 Its osteoinductive effect as well as the increased bone healing has been described in former studies.3 In addition to that, the results of our previous studies showed that local application of BMP-7 leads to a cytokine expression pattern similar to that of patients with proper bone healing.36,44 Since the application of both BMP-7 and ABG is helpful for bone healing, a combined treatment is successfully used for the therapy of atrophic non-unions.45,46 Yet, the safety of additional BMP-7 administration has never been assured on a molecular level comparing the cytokine expressions to an equivalent group that has received ABG alone. The high costs of BMP-7 can only be justified if the known beneficial effects are not overshadowed by pathologic growth factor expressions whose consequences are not fully understood yet. The use of cytokine expression analyses based on our standardized study protocol allows not only to decode the underlying mechanisms of successful bone regeneration but...
also to analyze the potential harm of additional osteogenic proteins on a molecular level.

**Limitations**

One limitation of this study is the low number of included patients in spite of the specialization in non-union treatment at our institution. However, this is partially due to the classification of patients into pairs and the strict matching criteria applied. Still, a perfect matching, especially, with regard to the patients’ age was not possible because of the heterogeneity of non-unions and their low incidence in clinical practice. Another limitation may arise from the differences in the age of samples as they were collected throughout the entire study period but analyzed at once, which could influence the cytokine concentrations.

**Strengths**

Advantages of this study are its cross-sectional design, standardized study protocol with strict clinical and radiologic follow-ups, clearly defined dates for the acquisition of blood samples and selection of patients according to specific matching criteria. Eventual radiologic and clinical consolidation of the operated non-unions could be ascertained in both study groups. The chronologic sequence of the cytokine measurements represents a reliable basis for the comparison of two treatment concepts. Our results assume that, with serum cytokine expression analysis, the safety of growth factor-based non-union treatment can be evaluated even with a small number of patients.

**Conclusion**

In this study, we could confirm the molecular safety of additional BMP-7 administration in non-union treatment within the diamond concept compared to a classic application of ABG by measuring the serum cytokines IGF-I, PDGF-AB and TGF-β. With the help of the serum cytokines, we conclude that the diamond concept is comparable to a therapy with ABG and without pathologic systemic expression of cytokines. With this established study protocol, the expression analysis of serum cytokines can be confirmed as a helpful method even with a low number of included patients. Yet, these findings have to be ascertained in studies with higher patient numbers.

**Acknowledgments**

The authors have revealed all financial and personal relationships to other persons and organizations that could inappropriately influence (bias) this work. We acknowledge the financial support of the Ruprecht-Karls-University of Heidelberg within the funding program Open Access Publishing.

**Disclosure**

GS is a consultant for Synthes (West Chester, PA, USA). The authors report no other conflicts of interest in this work.

**References**


Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines. This journal is indexed on PubMed Central, CAS, EMBASE, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.